new
coronaviru
cov
identifi
viru
etiolog
agent
respons
viral
pneumonia
outbreak
commenc
wuhan
current
target
therapeut
effect
treatment
option
remain
limit
order
rapidli
discov
lead
compound
clinic
use
initi
program
combin
structureassist
drug
design
virtual
drug
screen
highthroughput
screen
identifi
new
drug
lead
target
viru
main
proteas
pro
pro
key
cov
enzym
play
pivot
role
mediat
viral
replic
transcript
make
attract
drug
target
viru
identifi
mechanismbas
inhibitor
computeraid
drug
design
subsequ
determin
crystal
structur
viru
pro
complex
compound
next
combin
structurebas
virtual
highthroughput
screen
assay
compound
includ
approv
drug
drug
candid
clinic
trial
pharmacolog
activ
compound
inhibitor
pro
six
inhibit
pro
valu
rang
ebselen
also
exhibit
promis
antivir
activ
cellbas
assay
result
demonstr
efficaci
screen
strategi
lead
rapid
discoveri
drug
lead
clinic
potenti
respons
new
infecti
diseas
specif
drug
vaccin
avail
authorfund
right
reserv
reus
allow
without
permiss
biorxiv
preprint
cov
infect
human
anim
speci
caus
varieti
highli
preval
sever
diseas
includ
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
viru
genom
compris
nucleotid
replicas
gene
encod
two
overlap
polyprotein
requir
viral
replic
transcript
function
polypeptid
releas
polyprotein
extens
proteolyt
process
predominantli
main
proteas
pro
also
refer
proteas
pro
digest
polyprotein
less
conserv
site
start
autolyt
cleavag
enzym
function
import
pro
viral
life
cycl
togeth
absenc
close
relat
homologu
human
identifi
pro
attract
target
antivir
drug
design
facilit
rapid
discoveri
antivir
compound
clinic
potenti
develop
strategi
combin
structureassist
drug
design
virtual
drug
screen
highthroughput
screen
repurpos
exist
drug
target
viru
pro
establish
highthroughput
activ
assay
recombin
viru
pro
nativ
n
c
termini
express
escherichia
coli
subsequ
purifi
extend
data
fig
b
molecular
weight
viru
pro
determin
mass
spectroscopi
da
consist
theoret
molecular
weight
da
order
character
enzymat
activ
carri
highthroughput
screen
inhibitor
develop
fluoresc
reson
energi
transfer
fret
assay
fluoresc
label
substrat
dnp
deriv
ntermin
cleavag
sequenc
viral
proteas
design
synthes
timedepend
kinet
analysi
extend
data
fig
catalyt
effici
kcatkm
viru
pro
measur
slightli
higher
sar
cov
pro
higher
human
rhinoviru
proteas
previou
studi
design
michael
acceptor
inhibitor
use
computeraid
drug
design
cadd
extend
data
fig
specif
inhibit
multipl
cov
util
evalu
inhibit
approxim
pseudo
secondord
rate
suggest
michael
acceptor
potent
inhibit
crystal
structur
viru
pro
complex
order
elucid
inhibitori
mechan
compound
determin
crystal
structur
viru
pro
complex
resolut
asymmetr
unit
contain
one
polypeptid
extend
data
tabl
howev
two
associ
form
dimer
crystallograph
symmetri
axi
two
molecul
design
protom
b
fig
residu
residu
visibl
electron
densiti
map
protom
compos
three
domain
fig
domain
residu
residu
antiparallel
structur
domain
residu
contain
five
arrang
larg
antiparallel
globular
cluster
connect
domain
mean
long
loop
region
residu
one
side
residu
loop
link
domain
detail
specif
interact
pro
fig
electron
densiti
show
atom
form
coval
bond
vinyl
group
confirm
michael
addit
occur
subsit
absolut
requir
gln
posit
side
chain
protom
b
main
chain
involv
subsit
format
also
includ
two
order
water
molecul
name
lactam
insert
subsit
form
hydrogen
bond
side
chain
leu
site
insert
deepli
hydrophob
subsit
consist
side
chain
alkyl
portion
side
chain
side
chain
val
solventexpos
indic
site
form
van
der
waal
interact
addit
form
multipl
hydrogen
bond
main
chain
residu
substratebind
pocket
also
help
lock
inhibitor
insid
substratebind
pocket
conform
may
attribut
order
water
sarscov
pro
structur
make
longdist
hydrogen
bond
carboxyl
oxygen
ester
also
form
two
hydrogen
bond
backbon
nh
side
chain
previou
studi
propos
cov
pro
share
highli
conserv
substraterecognit
pocket
could
serv
drug
target
design
broadspectrum
inhibitor
recent
discoveri
new
cov
accumul
structur
data
cov
pro
variou
speci
provid
opportun
examin
hypothesi
superposit
crystal
structur
pro
shown
variabl
region
helic
domain
surfac
loop
substratebind
pocket
locat
cleft
domain
still
highli
conserv
among
cov
pro
suggest
antivir
inhibitor
target
site
widespectrum
anticov
activ
fig
c
howev
detergentbas
assay
found
aggregatebas
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
inhibitor
might
nonspecif
inhibit
pro
extend
data
fig
therefor
consid
investig
next
set
identifi
potenti
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
respect
fig
c
doserespons
curv
suggest
could
abl
penetr
cellular
membran
access
target
ebselen
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
pharmaceut
drug
drug
candid
provid
altern
approach
rapidli
identifi
potenti
drug
lead
manag
rapidli
emerg
viral
infect
cellbas
phenotyp
screen
proven
valuabl
complex
approach
readili
compat
highthroughput
pipelin
identifi
molecular
target
mechan
action
studi
converg
structurebas
ab
initio
drug
design
virtual
screen
highthroughput
screen
prove
effici
strategi
find
antivir
lead
viru
method
present
greatli
assist
rapid
discoveri
drug
lead
clinic
potenti
respons
new
emerg
infecti
diseas
current
lack
specif
drug
vaccin
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
method
sulfur
use
replac
calcul
obtain
optim
superposit
molecul
use
assess
reason
predict
bind
pose
two
dock
method
bind
orient
consist
among
differ
method
kept
construct
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
initi
complex
final
complex
optim
rescor
use
mmgbsa
modul
residu
within
around
ligand
refin
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
databas
releas
nov
contain
use
protein
discover
order
accur
estim
peptid
probabl
fals
discoveri
rate
fdr
use
decoy
databas
contain
revers
sequenc
protein
append
target
databas
fdr
set
mass
toler
precursor
ion
set
ppm
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
